.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB06_Ganciclovir.Ganciclovir_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB06_Ganciclovir.Ganciclovir_1| name: | Ganciclovir_1 | |
| ATC code: | J05AB06_1 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 350 | mg |
| volume of distribution: | 0.67 | L |
| clearance: | 3.8 | mL/min/kg |
| other parameters in model implementation | ||
Ganciclovir is an antiviral medication used for the treatment and prevention of cytomegalovirus (CMV) infections in immunocompromised individuals. It remains an essential antiviral for this indication.
Population pharmacokinetics model in renal transplant recipients; intravenous administration of 5 mg/kg.
Nguyen, T, et al., & Hirt, D (2021). Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. Antimicrobial agents and chemotherapy 65(3) –. DOI:10.1128/AAC.02254-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33318012
Selby, PR, et al., & Roberts, JA (2023). Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients. Antimicrobial agents and chemotherapy 67(3) e0155022–None. DOI:10.1128/aac.01550-22 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36815858
Li, S, et al., & Wang, Y (2020). Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children. Frontiers in pharmacology 11 614164–None. DOI:10.3389/fphar.2020.614164 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33536921